VTEX
VTEX's revenue rose 6.1% to $240 million in fiscal 2025. Its operating margin was 7.5%, up from 3.3% a year earlier. Free cash flow was $32 million, up 35.3%. It paid out $59 million in dividends and buybacks, 183% of free cash flow. The diluted share count fell 3.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
From fiscal 2024 to 2025, earnings per share grew 37.5% a year and net income 26.6% a year, as buybacks cut the share count by 4%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 298 | 239 | 209 | 215 | 192 |
| Debt incl. finance leases | 3 | 1 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −295 | −237 | −209 | −215 | −192 |
| Net debt to EBITDA | — | — | — | −20.2x | −9.0x |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −701.4x | −805.1x | −3,511.2x | — | — |
| Current ratio | 5.9x | 4.6x | 3.5x | 3.6x | 3.0x |
| Quick ratio | 5.9x | 4.6x | 3.5x | 3.6x | 3.0x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 7 of 9 | 7 of 9 | 6 of 9 |
| Rule of 40 | 30.3% | 23.0% | 19.5% |
| Altman Z'' | 4.56 | 5.33 | 5.07 |
| Accruals ratio | −6.1% | −2.9% | −3.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Pass | Fail | Pass |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 7 of 9 | 7 of 9 | 6 of 9 |
Compare
Put VTEX side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| VTEX | FY25 | 6.1% | 7.5% | 13.4% | 39.9% | −9.0x | 6 | |
| Definitive Healthcare | FY25 | −4.2% | −92.9% | 15.3% | −38.3% | — | 5 | Compare |
| Docebo | FY25 | 11.9% | 9.6% | 11.2% | — | −2.8x | 5 | Compare |
| OneSpan | FY25 | 0.0% | 19.9% | 20.8% | — | — | — | Compare |
| C3.ai | FY26 | −35.7% | −199.2% | −76.8% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 61 | 99 | 126 | 158 | 202 | 227 | 240 |
| Revenue growth | — | 60.9% | 27.5% | 25.3% | 27.9% | 12.5% | 6.1% |
| Gross profit | 41 | 64 | 76 | 105 | 140 | 167 | 186 |
| Research and development | 13 | 19 | 45 | 57 | 60 | 55 | 64 |
| Operating income | −2 | 6 | −66 | −50 | −14 | 7 | 18 |
| Net income | −5 | −1 | −60 | −52 | −16 | 16 | 20 |
| Diluted EPS (US$) | — | −0.01 | −0.33 | −0.28 | −0.09 | 0.08 | 0.11 |
| Diluted shares (millions) | — | — | 182 | 191 | 186 | 192 | 185 |
| Cash flow | |||||||
| Cash from operations | 2 | 11 | −53 | −29 | 5 | 26 | 33 |
| Capital expenditure | 2 | 2 | 1 | 0 | 0 | 2 | 1 |
| Free cash flow | 0 | 10 | −54 | −30 | 5 | 24 | 32 |
| Dividends paid | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 35 | 11 | 59 |
| Acquisitions | 3 | 4 | 6 | 2 | 0 | 3 | 4 |
| Stock-based compensation | 1 | 3 | 9 | 12 | 16 | 17 | 17 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 30 | 76 | 298 | 239 | 209 | 215 | 192 |
| Debt incl. finance leases | — | 6 | 3 | 1 | 0 | 0 | 0 |
| Total assets | — | 140 | 415 | 358 | 341 | 362 | 347 |
| Total liabilities | — | 64 | 88 | 85 | 102 | 108 | 113 |
| Shareholders' equity | 47 | 76 | 327 | 275 | 240 | 254 | 234 |
| Margins and ratios | |||||||
| Gross margin | 67.0% | 64.7% | 60.6% | 66.5% | 69.4% | 73.6% | 77.5% |
| Operating margin | −3.0% | 6.6% | −52.4% | −31.7% | −7.0% | 3.3% | 7.5% |
| Net margin | −7.5% | −0.9% | −48.1% | −33.3% | −7.9% | 7.0% | 8.3% |
| Free cash flow margin | 0.4% | 9.6% | −43.2% | −18.8% | 2.5% | 10.5% | 13.4% |
| Rule of 40 (growth + FCF margin) | — | 70.5% | −15.8% | 6.6% | 30.3% | 23.0% | 19.5% |
| Return on capital | — | — | — | — | — | — | 39.9% |
| Return on equity | — | — | −30.0% | −17.4% | −6.2% | 6.4% | 8.2% |
| Return on assets | — | — | −21.8% | −13.6% | −4.5% | 4.5% | 5.7% |
| Net debt to EBITDA | — | −7.8x | — | — | — | −20.2x | −9.0x |